Summary | |
---|---|
Symbol | CP |
Name | ceruloplasmin (ferroxidase) |
Aliases | CP-2; Ferroxidase; Ceruloplasmin |
Chromosomal Location | 3q23-q25 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Secreted. Note=Colocalizes with GCP1 in secretory intracellular compartments. |
Domain |
PF00394 Multicopper oxidase PF07731 Multicopper oxidase PF07732 Multicopper oxidase |
Function |
Ceruloplasmin is a blue, copper-binding (6-7 atoms per molecule) glycoprotein. It has ferroxidase activity oxidizing Fe(2+) to Fe(3+) without releasing radical oxygen species. It is involved in iron transport across the cell membrane. Provides Cu(2+) ions for the ascorbate-mediated deaminase degradation of the heparan sulfate chains of GPC1. May also play a role in fetal lung development or pulmonary antioxidant defense (By similarity). |
Biological Process |
GO:0000041 transition metal ion transport GO:0006825 copper ion transport GO:0006875 cellular metal ion homeostasis GO:0006879 cellular iron ion homeostasis GO:0046916 cellular transition metal ion homeostasis GO:0055072 iron ion homeostasis GO:0055076 transition metal ion homeostasis |
Molecular Function |
GO:0004322 ferroxidase activity GO:0005507 copper ion binding GO:0016722 oxidoreductase activity, oxidizing metal ions GO:0016724 oxidoreductase activity, oxidizing metal ions, oxygen as acceptor GO:0051087 chaperone binding |
Cellular Component |
GO:0005765 lysosomal membrane GO:0072562 blood microparticle GO:0098852 lytic vacuole membrane |
KEGG |
hsa00860 Porphyrin and chlorophyll metabolism |
Reactome |
R-HSA-917937: Iron uptake and transport R-HSA-425410: Metal ion SLC transporters R-HSA-425407: SLC-mediated transmembrane transport R-HSA-382551: Transmembrane transport of small molecules R-HSA-425366: Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds |
Summary | |
---|---|
Symbol | CP |
Name | ceruloplasmin (ferroxidase) |
Aliases | CP-2; Ferroxidase; Ceruloplasmin |
Chromosomal Location | 3q23-q25 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between CP and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | CP |
Name | ceruloplasmin (ferroxidase) |
Aliases | CP-2; Ferroxidase; Ceruloplasmin |
Chromosomal Location | 3q23-q25 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of CP in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | CP |
Name | ceruloplasmin (ferroxidase) |
Aliases | CP-2; Ferroxidase; Ceruloplasmin |
Chromosomal Location | 3q23-q25 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of CP in various data sets.
|
Points in the above scatter plot represent the mutation difference of CP in various data sets.
|
Summary | |
---|---|
Symbol | CP |
Name | ceruloplasmin (ferroxidase) |
Aliases | CP-2; Ferroxidase; Ceruloplasmin |
Chromosomal Location | 3q23-q25 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CP. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | CP |
Name | ceruloplasmin (ferroxidase) |
Aliases | CP-2; Ferroxidase; Ceruloplasmin |
Chromosomal Location | 3q23-q25 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CP. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CP. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | CP |
Name | ceruloplasmin (ferroxidase) |
Aliases | CP-2; Ferroxidase; Ceruloplasmin |
Chromosomal Location | 3q23-q25 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CP. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | CP |
Name | ceruloplasmin (ferroxidase) |
Aliases | CP-2; Ferroxidase; Ceruloplasmin |
Chromosomal Location | 3q23-q25 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of CP expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | CP |
Name | ceruloplasmin (ferroxidase) |
Aliases | CP-2; Ferroxidase; Ceruloplasmin |
Chromosomal Location | 3q23-q25 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between CP and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | CP |
Name | ceruloplasmin (ferroxidase) |
Aliases | CP-2; Ferroxidase; Ceruloplasmin |
Chromosomal Location | 3q23-q25 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting CP collected from DrugBank database. |
Details on drugs targeting CP.
|